Posted by Michael Wonder on 30 Nov 2021
Over 600 people set to benefit from innovative lung cancer treatment within the Cancer Drugs Fund
30 November 2021 - More than 600 people could benefit from an innovative drug for a form of lung cancer as NICE publishes final draft guidance recommending osimertinib within the Cancer Drugs Fund.
Osimertinib (Tagrisso; AstraZeneca) is recommended for people with early-stage (1b to 3a) non-small-cell lung cancer who have had surgery to remove their tumour and who have epidermal growth factor receptor gene mutations.
